Research Radartracking 1,138 published studies · 277 human · 6 safety signals · 42 clinical trials · 44 cancer pages · updated Jul 2026Open the Research Map →

Relacorilant

← All agents

Human-reviewed · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

Evidence at a glanceHuman trial / meta-analysisMixed results⚠ Studies disagree
4 published studies tagged to this agent3 human studies approved & graded (trial, observational, or meta-analysis)
Why this grade?

Human trial / meta-analysis — Includes human trial or meta-analysis evidence.

Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.

Auto-discovered · not yet curatedrelacorilant
Educational only, not medical advice. OncoForge makes no claim that Relacorilant treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Simple Summary

Auto-discovered from 1 recent study; not yet curated.

Research

Where the evidence is

What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.

CancerHuman evidenceMechanismSafetyTrial
Fallopian Tube Cancer34—3
Primary Peritoneal Cancer34—3
Epithelial Ovarian Cancer12—1
Advanced Platinum Resistant Ovarian Cancer11—1
Ovarian Cancer11—1
Ovarian Carcinosarcoma11—1
Ovarian Epithelial Carcinoma11—1
Platinum Resistant Ovarian Cancer11—1
Recurrent Platinum Resistant High Grade Serous Epithelial Ovarian Cancer11—1
Pancreatic Cancer—1——
Prostate Cancer—1——

Reported figures

Study mix

4 published studies by what they were done in. Lab and animal findings often do not carry over to people.

3 Human1 Review/other
Reported directionReported positive2Mixed results1Inconclusive1

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline
0
Meta-analysis
0
Systematic review
0
Randomized trial
0
Clinical trial
3
Observational
0
Case report
0
Review
1
Preclinical
0
Other
0
4 studies3 human1 review/other

Tracking 4 published studies of Relacorilant: 3 in humans, 1 reviews/other.

Reported direction across studies: 2 positive, 1 mixed, 1 inconclusive.

Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.

These counts summarize what the studies reported; they are not a measure of whether Relacorilant works.

Cancers named in these studies

fallopian tube cancer (4)primary peritoneal cancer (4)epithelial ovarian cancer (2)pancreatic cancer (1)prostate cancer (1)platinum-resistant ovarian cancer (1)advanced platinum-resistant ovarian cancer (1)recurrent platinum-resistant high-grade serous epithelial ovarian cancer (1)ovarian cancer (1)ovarian epithelial carcinoma (1)

Conflicting evidence

All studies

ReviewReported positiveLimited evidenceTier 4 · clinical

Relacorilant: First Approval

Drugs · Jun 2026 · regulatory approval summary

Relacorilantepithelial ovarian cancerfallopian tube cancerprimary peritoneal cancerpancreatic cancerprostate cancer

Relacorilant is a non-steroidal, selective glucocorticoid receptor antagonist being developed for several solid tumours and Cushing syndrome. The article reports that relacorilant received its first approval in the USA on 25 March 2026 for use in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after 1-3 prior systemic regimens (at least one including bevacizumab). The article summarizes development milestones leading to this approval.

Studied with: nab-paclitaxel.

Key findings
  • Relacorilant is a non-steroidal, selective glucocorticoid receptor II antagonist developed by Corcept Therapeutics.
  • Relacorilant received first approval in the USA on 25 March 2026.
  • Approval is for use in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens, at least one of which included bevacizumab.
  • Relacorilant is being developed for various solid tumours including ovarian, fallopian tube, peritoneal, pancreatic and prostate cancers, as well as for Cushing syndrome.
  • The article summarizes milestones in the development of relacorilant leading to this approval.
Limitations: Abstract provides no efficacy or safety outcome data or numeric results from trials.; No trial design, sample size, or methods are reported in the abstract.; This is an approval/summary article, not primary trial data.; Geographic scope limited to a USA approval; supporting evidence is not detailed in the abstract..

AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed

Human trialTrialReported positiveStrong evidenceTier 4 · clinicaln = 381

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

Lancet (London, England) · Jun 2025 · randomized, controlled, open-label phase 3 trial

Relacorilantplatinum-resistant ovarian cancerepithelial ovarian cancerprimary peritoneal cancerfallopian tube cancer

This phase 3 randomized trial tested whether adding relacorilant to nab-paclitaxel helped women with platinum-resistant ovarian cancer. The combination improved progression-free survival and also showed a longer overall survival at an interim analysis. Side effects were similar between groups after accounting for nab-paclitaxel exposure, and no new safety signals were seen.

Reported effects: progression-free survival hazard ratio 0.7 [0.54–0.91], p p=0.0076, n=381 · progression-free survival median 6.54 mo [5.55–7.43], n=188 · +3 more

Studied with: nab-paclitaxel.

Key findings
  • Progression-free survival was significantly longer with relacorilant plus nab-paclitaxel than with nab-paclitaxel alone.
  • An interim overall survival analysis also favored the combination.
  • Adverse events were similar across groups when adjusted for nab-paclitaxel exposure; no new safety signals were observed.
Limitations: Open-label design; Overall survival result was based on a planned interim analysis; Trial is ongoing; Funding from the drug manufacturer.

This study evaluated relacorilant as an added anticancer agent in platinum-resistant ovarian cancer.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

Human trialTrialInconclusiveModerate evidenceTier 4 · clinical

Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer

Journal of gynecologic oncology · Jul 2024 · phase 3, randomized, 2-arm, open-label, global multicenter study protocol

Relacorilantadvanced platinum-resistant ovarian cancerrecurrent platinum-resistant high-grade serous epithelial ovarian cancerprimary peritoneal cancerfallopian tube cancer

This paper describes the ROSELLA phase 3 trial, which is testing relacorilant plus nab-paclitaxel versus nab-paclitaxel alone in women with recurrent platinum-resistant ovarian and related cancers. The study is designed to see whether adding relacorilant improves progression-free survival and other outcomes, and it will also assess safety and patient-reported outcomes. The abstract does not report trial results, only the study plan.

Studied with: nab-paclitaxel.

Key findings
  • ROSELLA is a phase 3, randomized, 2-arm, open-label, global multicenter study.
  • Participants are assigned 1:1 to relacorilant plus nab-paclitaxel or nab-paclitaxel monotherapy.
  • Primary endpoint is progression-free survival assessed by blinded independent central review.
  • Secondary endpoints include overall survival, objective response rate, duration of response, clinical benefit rate at 24 weeks, and CA-125 response.
  • The abstract reports no efficacy or safety results because it is a trial protocol.
Limitations: Protocol only; no outcomes or results are reported in the abstract.; No sample size is provided in the abstract.; No quantitative effect estimates are available.; Open-label design may introduce bias in some endpoints..

This is a phase 3 protocol in platinum-resistant ovarian cancer evaluating an anticancer combination.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human trialTrialMixed resultsModerate evidenceTier 4 · clinicaln = 178

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Oct 2023 · three-arm, randomized, controlled, open-label phase II study

Relacorilantovarian cancerovarian epithelial carcinomaprimary peritoneal cancerfallopian tube cancerovarian carcinosarcoma

This phase II study tested relacorilant added to nab-paclitaxel in women with recurrent platinum-resistant or refractory ovarian and related cancers. The intermittent relacorilant schedule improved progression-free survival and duration of response compared with nab-paclitaxel alone, while overall response rate was similar across groups. Side effects were broadly comparable between arms, and the study did not meet its prespecified statistical threshold after multiplicity adjustment.

Reported effects: PFS HR 0.66, p P = .038, n=178 · DOR HR 0.36, p P = .006, n=178 · +1 more

Studied with: nab-paclitaxel.

Key findings
  • Intermittent relacorilant plus nab-paclitaxel improved PFS versus nab-paclitaxel monotherapy (HR 0.66; P = .038).
  • Intermittent relacorilant plus nab-paclitaxel improved DOR versus nab-paclitaxel monotherapy (HR 0.36; P = .006).
  • ORR was similar across arms.
  • At the preplanned OS analysis, the OS HR was 0.67 with P = .066 for the intermittent arm versus nab-paclitaxel monotherapy.
  • Continuous relacorilant plus nab-paclitaxel showed numerically improved median PFS but no significant improvement over monotherapy.
  • Adverse events were comparable across study arms; common grade ≥3 events included neutropenia, anemia, peripheral neuropathy, and fatigue/asthenia.
Limitations: Phase II study with relatively small sample size.; Open-label design.; Primary end point did not reach statistical significance after protocol-prespecified Hochberg step-up multiplicity adjustment.; Median follow-up was limited for PFS and OS analyses.; Safety and efficacy were compared against nab-paclitaxel monotherapy, but the abstract does not provide detailed absolute event rates..

Relacorilant was studied as an add-on to chemotherapy in recurrent platinum-resistant ovarian cancer.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

What changed recently

The latest additions to Relacorilant's evidence base, and anything that's been retracted.

Recently added

Cancers where Relacorilant reported positive results

Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.

Human evidence

Epithelial ovarian cancer2 positive1 human
Limitations: Abstract provides no efficacy or safety outcome data or numeric results from trials.; No trial design, sample size, or methods are reported in the abstract.; This is an approval/summary article, not primary trial data.; Geographic scope limited to a USA approval; supporting evidence is not detailed in the abstract.; Open-label design; Overall survival result was based on a planned interim analysis.
Cited positive studies (2)
Fallopian tube cancer2 positive1 negative/mixed3 human
Limitations: Abstract provides no efficacy or safety outcome data or numeric results from trials.; No trial design, sample size, or methods are reported in the abstract.; This is an approval/summary article, not primary trial data.; Geographic scope limited to a USA approval; supporting evidence is not detailed in the abstract.; Open-label design; Overall survival result was based on a planned interim analysis.
Cited positive studies (2)
Primary peritoneal cancer2 positive1 negative/mixed3 human
Limitations: Abstract provides no efficacy or safety outcome data or numeric results from trials.; No trial design, sample size, or methods are reported in the abstract.; This is an approval/summary article, not primary trial data.; Geographic scope limited to a USA approval; supporting evidence is not detailed in the abstract.; Open-label design; Overall survival result was based on a planned interim analysis.
Cited positive studies (2)
Platinum-resistant ovarian cancer1 positive1 human
Limitations: Open-label design; Overall survival result was based on a planned interim analysis; Trial is ongoing; Funding from the drug manufacturer.
Cited positive studies (1)
Preclinical only: lab / animal (2)
Limitations: Abstract provides no efficacy or safety outcome data or numeric results from trials.; No trial design, sample size, or methods are reported in the abstract.; This is an approval/summary article, not primary trial data.; Geographic scope limited to a USA approval; supporting evidence is not detailed in the abstract..
Cited positive studies (1)
Prostate cancer1 positive
Limitations: Abstract provides no efficacy or safety outcome data or numeric results from trials.; No trial design, sample size, or methods are reported in the abstract.; This is an approval/summary article, not primary trial data.; Geographic scope limited to a USA approval; supporting evidence is not detailed in the abstract..
Cited positive studies (1)

Evidence at a glance: Relacorilant by cancer

A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.

Fallopian tube cancerHuman trial / meta-analysisMixed results3 human

Includes human trial or meta-analysis evidence.

Largest credible effect: progression-free survival hazard ratio 0.7 [0.54–0.91], p p=0.0076, n=381 PMID 40473448 · hazard ratios 0.36–0.7 across 5 studies

Most authoritative study: Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

Findings conflict across studies · Effect sizes reported in only 2 of 4 studies.
Primary peritoneal cancerHuman trial / meta-analysisMixed results3 human

Includes human trial or meta-analysis evidence.

Largest credible effect: progression-free survival hazard ratio 0.7 [0.54–0.91], p p=0.0076, n=381 PMID 40473448 · hazard ratios 0.36–0.7 across 5 studies

Most authoritative study: Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

Findings conflict across studies · Effect sizes reported in only 2 of 4 studies.
Epithelial ovarian cancerHuman trial / meta-analysisReported positive1 human

Includes human trial or meta-analysis evidence.

Largest credible effect: progression-free survival hazard ratio 0.7 [0.54–0.91], p p=0.0076, n=381 PMID 40473448 · median-survival values 6.54–15.97 across 3 studies

Most authoritative study: Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

Effect sizes reported in only 1 of 2 studies.
Advanced platinum-resistant ovarian cancerHuman trial / meta-analysisInconclusive1 human

Includes human trial or meta-analysis evidence.

Most authoritative study: Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer

No numeric effect sizes reported · Based on a single study.
Ovarian cancerHuman trial / meta-analysisMixed results1 human

Includes human trial or meta-analysis evidence.

Largest credible effect: PFS HR 0.66, p P = .038, n=178 PMID 37364223 · hazard ratios 0.36–0.67 across 3 studies

Most authoritative study: Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

Based on a single study.
Ovarian carcinosarcomaHuman trial / meta-analysisMixed results1 human

Includes human trial or meta-analysis evidence.

Largest credible effect: PFS HR 0.66, p P = .038, n=178 PMID 37364223 · hazard ratios 0.36–0.67 across 3 studies

Most authoritative study: Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

Based on a single study.
Ovarian epithelial carcinomaHuman trial / meta-analysisMixed results1 human

Includes human trial or meta-analysis evidence.

Largest credible effect: PFS HR 0.66, p P = .038, n=178 PMID 37364223 · hazard ratios 0.36–0.67 across 3 studies

Most authoritative study: Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

Based on a single study.
Platinum-resistant ovarian cancerHuman trial / meta-analysisReported positive1 human

Includes human trial or meta-analysis evidence.

Largest credible effect: progression-free survival hazard ratio 0.7 [0.54–0.91], p p=0.0076, n=381 PMID 40473448 · median-survival values 6.54–15.97 across 3 studies

Most authoritative study: Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

Based on a single study.
Recurrent platinum-resistant high-grade serous epithelial ovarian cancerHuman trial / meta-analysisInconclusive1 human

Includes human trial or meta-analysis evidence.

Most authoritative study: Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer

No numeric effect sizes reported · Based on a single study.
Pancreatic cancerInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Relacorilant: First Approval

No human studies yet · No numeric effect sizes reported · Based on a single study.
Prostate cancerInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Relacorilant: First Approval

No human studies yet · No numeric effect sizes reported · Based on a single study.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of Relacorilant depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.
Doses reported in studies

Trials studying Relacorilant

Loading current trials from ClinicalTrials.gov… Search ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar